Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 8Neoplasms 2Recurrence 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroblastoma 1Neoplasm Metastasis 1Granulosa Cell Tumor 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Castration-resistant Prostate Cancer 1Brain Neoplasms 1Astrocytoma 1

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × Ketoconazole × Clear all
NCT01535157 2020-08-27

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

South Plains Oncology Consortium

Phase 1/2 Terminated
12 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡